期刊
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
卷 14, 期 -, 页码 -出版社
MATTIOLI 1885
DOI: 10.4084/MJHID.2022.043
关键词
Acute lymphoblastic leukemia; COVID-19; Inotuzumab; Remdesevir; Convalescent plasma
资金
- Associazione Italiana per la Ricerca sul Cancro (AIRC), Metastases Special Program, Milan, Italy [21198]
- Progetti di Rilevante Interesse Nazionale (PRIN) Italia [2017PPS2X4]
This article describes the clinical history of a patient with concomitant acute lymphoblastic leukemia (ALL) and COVID-19 infection. The patient developed Sars-CoV2 prior to treatment initiation, but was asymptomatic for COVID-19. Despite respiratory findings worsening during treatment, the patient achieved complete hematologic remission without completing the full treatment cycle and spontaneously developed anti-Sars-CoV-2 antibodies. After COVID-19 recovery, the patient underwent transplantation and achieved complete remission.
Management of patients with concomitant acute lymphoblastic leukemia (ALL) and COVID-19 infection is challenging. We describe the clinical history of a 40-year-old male with relapsed B-common ALL who developed Sars-CoV2 prior to treatment initiation with inotuzumab. Since the patient was asymptomatic for COVID-19, the first dose of inotuzumab was administered, followed by remdesivir as prophylaxis. However, a worsening in respiratory findings led to a delay in administering the following doses of inotuzumab. Interestingly, even if the patient did not receive the full inotuzumab cycle, he achieved a complete hematologic remission: furthermore, he spontaneously developed anti-sars-COV2 antibodies. COVID-19 treatment also included convalescent plasma, leading to negativization of the viral load. The patient, after COVID-19 recovery, received a second full cycle of inotuzumab, underwent allogeneic transplantation, and is currently in complete hematologic and molecular remission, in good clinical conditions, five months from allograft.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据